Role of n-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport

Journal of Pharmaceutical Sciences

Volumn 94, Issue 4, 2005, Pages 912-917

  Lee, Philip J ^a   Langer, Robert ^a   Shastri, V Prasad ^a,b  

^a Massachusetts Institute of Technology   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Formulation; Hydrophilic; Lidocaine; n methyl pyrrolidone; Permeability; Permeation enhancers; Skin; Transdermal drug delivery

Indexed keywords

LIDOCAINE; N METHYLPYRROLIDONE; PRILOCAINE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; HUMAN TISSUE; HYDROPHILICITY; HYDROPHOBICITY; STRATUM CORNEUM;

EID: 17744362321     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20291     Document Type: Article

References (26)

1. Asbill CS, El-Kattan AF, Michniak B. 2000. Enhancement of transdermal drug delivery: Chemical and physical approaches. Grit Rev Ther Drug Carrier Syst 17:621-658.
2. Ranade VV. 1991. Drug delivery systems. 6. Transdermal drug delivery. Clin Pharmacol 31:401-418.
3. Gale RM, Enscore DJ. 1987. Transdermal delivery of highly ionized fat insoluble drugs. US Patent No. 4,645,502. ALZA Corporation.
4. Yoneto K, Li SK, Ghanem AH, Crommelin DJ, Higuchi WI. 1995. A mechanistic study of the effects of the 1-alkyl-2-pyrrolidones on bilayer permeability of stratum corneum lipid liposomes: A comparison with hairless mouse skin studies. J Pharm Sci 84:853-860.
5. Lee PJ, Langer RS, Shastri VP. 2003. Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs. Pharm Res 20:264-269.
6. Francoeur ML, Golden GM, Potts RO. 1990. Oleic acid: Its effects on stratum corneum in relation to (trans)dermal drug delivery. Pharm Res 7:621-627.
7. Kim DD, Chien YW. 1996. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J Pharm Sci 85:214-219.
8. Barry BW, Bennett SL. 1987. Effect of penetration enhancers on the permeation of mannitol, hydrocortisone and progesterone through human skin. J Pharm Pharmacol 39:535-546.
9. Gorukanti SR, Li L, Kim KH. 1999. Transdermal delivery of antiparkinsonian agent, benztropine. Int J Pharm 192:159-172.
10. Roy SD, Roos E, Sharma K. 1994. Transdermal delivery of buprenorphine through cadaver skin. J Pharm Sci 83:126-130.
11. Peck KD, Ghanem AH, Higuchi WI. 1995. The effect of temperature upon the permeation of polar and ionic solutes through human epidermal membranes. J Pharm Sci 84:975-982.
12. Johnson ME, Mitragotri S, Patel A, Blankschtein D, Langer R. 1996. Synergistic effects of chemical enhancers and therapeutic ultrasound on transdermal drug delivery. J Pharm Sci 85:670-679.
13. Sasaki H, Kojima M, Nakamura J, Shibasaki J. 1990. Enhancing effect of combining two pyrrolidone vehicles on transdermal drug delivery. J Pharm Pharmacol 42:196-199.
14. Pugh WJ, Hadgraft J, Roberts MS. 1996. Epidermal permeability-Penetrant structure relationships: 3. The effect of hydrogen bonding interactions and molecular size on diffusion across the stratum corneum. Int J Pharm 138:149-165.
15. Liu P, Kurihara-Bergstrom T, Good WR. 1991. Cotransport of estradiol and ethanol through human skin in vitro: Understanding the permeant/enhancer flux relationship. Pharm Res 8:938-944.
16. Cross SE, Pugh WJ, Hadgraft J, Roberts MS. 2001. Probing the effect of vehicles on topical delivery: Understanding the basic relationship between solvent and solute penetration using silicone membranes. Pharm Res 18:999-1005.
17. Ollmar S, Nicander I. 1995. Information in multi-frequency measurement on intact skin. Innov Tech Biol Med 16:745-751.
18. Williams AC, Barry BW. 1992. Skin absorption enhancers. Crit Rev Ther Drug Carrier Syst 9:305-353.
19. Tarantino R, Bishop E, Chen FC, Iqbal K, Malick AW. 1994. N-methyl-2-pyrrolidone as a cosolvent: Relationship of cosolvent effect with solute polarity and the presence of proton-donating groups on model drug compounds. J Pharm Sci 83:1213-1216.
20. Berner B, Mazzenga GC, Otte JH, Steffens RJ, Juang R, Ebert CD. 1989. Ethanol:water mutually enhanced transdermal therapeutic system. II. Skin permeation of ethanol and nitroglycerin. J Pharm Sci 78:402-407.
21. He N, Li SK, Suhonen TM, Warner KS, Higuchi WI. 2003. Mechanistic study of alkyl azacycloheptanones as skin permeation enhancers by permeation and partition experiments with hairless mouse skin. J Pharm Sci 92:297-310.
22. Payan JP, Boudry I, Beydon D, Fabry JP, Grandclaude MC, Ferrari E, Andre JC. 2003. Toxicokinetics and metabolism of N-[(14)C]N-methyl-2-pyrrolidone in male Sprague-Dawley rats: In vivo and in vitro percutaneous absorption. Drug Metab Dispos 31:659-669.
23. Akrill P, Cocker J, Dixon S. 2002. Dermal exposure to aqueous solutions of N-methyl pyrrolidone. Toxicol Lett 134:265-269.
24. Leira HL, Tiltnes A, Svendsen K, Vetlesen L. 1992. Irritant cutaneous reactions to N-methyl-2-pyrrolidone (NMP). Contact Dermatitis 27:148-150.
25. Mitragotri S. 2000. Synergistic effect of enhancers for transdermal drug delivery. Pharm Res 17: 1354-1358.
26. Neubert R, Rettig W, Wartewig S, Wegener M, Wienhold A. 1997. Structure of stratum corneum lipids characterized by FT-Raman spectroscopy and DSC. II. Mixtures of ceramides and saturated fatty acids. Chem Phys Lipids 89:3-14.